Literature DB >> 31938374

Serum miR-126-3p level is down-regulated in sepsis patients.

Chao Chen1, Lidan Zhang1, Huimin Huang1, Shanshan Liu1, Yujian Liang1, Lingling Xu1, Suping Li1, Yucai Cheng1,2, Wen Tang1.   

Abstract

BACKGROUND: Endothelial injury is part of the pathogenesis of sepsis. The microRNA-126 (miR-126) was previously identified as an endothelial biomarker and is known to play a critical role in preserving endothelial cell integrity. However, the role of miRNA-126 in sepsis is unclear.
METHOD: Blood samples were collected from sepsis patients at the first Affiliated Hospital of Sun Yat-sen University within 24 h (n = 60) and on day 7 (n = 51) after diagnosis, and once from control subjects (n = 46). MiR-126-3p expression was evaluated by quantitative real-time PCR. The miR-126-3p level was correlated with clinical data and a set of routine and experimental biomarkers. The outcome of sepsis patients was determined by follow-up at 28 days after collection of blood samples on day 7. RESULT: MiR-126-3p level was significantly downregulated in sepsis patients 24 h after diagnosis compared with control subjects. Degree of downregulation of serum miR-126-3p correlated with the severity of sepsis. To determine the diagnostic accuracy of miR-126-3p, the receiver operating characteristic (ROC) was performed and the AUC of miR-126-3p was 0.735. Furthermore, serum miR-126-3p concentration at this time point was correlated with the expression markers of systemic inflammation, bacterial infection, and renal and hepatic dysfunction. However, serum miR-126-3p level on day 7 day did not differ between surviving sepsis patients and those who died.
CONCLUSION: These results indicate that miR-126-3p could be a diagnostic biomarker for sepsis. IJCEP
Copyright © 2018.

Entities:  

Keywords:  Sepsis; diagnosis; endothelial injury; miR-126-3p; prognosis

Year:  2018        PMID: 31938374      PMCID: PMC6958305     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  7 in total

1.  Influences of Regulation of miR-126 on Inflammation,Th17/Treg Subpopulation Differentiation, and Lymphocyte Apoptosis through Caspase Signaling Pathway in Sepsis.

Authors:  Qi Zou; Mei Yang; Meiling Yu; Cheng Liu
Journal:  Inflammation       Date:  2020-12       Impact factor: 4.092

2.  Therapeutic Potential of Extracellular Vesicles for Sepsis Treatment.

Authors:  Stephanie M Kronstadt; Alex E Pottash; Daniel Levy; Sheng Wang; Wei Chao; Steven M Jay
Journal:  Adv Ther (Weinh)       Date:  2021-04-29

3.  Can Be miR-126-3p a Biomarker of Premature Aging? An Ex Vivo and In Vitro Study in Fabry Disease.

Authors:  Alessia Lo Curto; Simona Taverna; Maria Assunta Costa; Rosa Passantino; Giuseppa Augello; Giorgia Adamo; Anna Aiello; Paolo Colomba; Carmela Zizzo; Marco Zora; Giulia Accardi; Giuseppina Candore; Daniele Francofonte; Tiziana Di Chiara; Riccardo Alessandro; Calogero Caruso; Giovanni Duro; Giuseppe Cammarata
Journal:  Cells       Date:  2021-02-09       Impact factor: 6.600

4.  MiR-940 Serves as a Diagnostic Biomarker in Patients with Sepsis and Regulates Sepsis-Induced Inflammation and Myocardial Dysfunction.

Authors:  Shijuan Zhang; Yuhong Wei; Jinxia Liu; Yutian Zhuang
Journal:  J Inflamm Res       Date:  2021-09-09

5.  miR-126 ameliorates multiple organ dysfunction in septic rats by regulating the differentiation of Th17/Treg.

Authors:  Qi Zou; Cheng Liu; Nan Hu; Wei Wang; Huaxue Wang
Journal:  Mol Biol Rep       Date:  2022-02-05       Impact factor: 2.742

Review 6.  Modes of action and diagnostic value of miRNAs in sepsis.

Authors:  Nikolaos Antonakos; Charly Gilbert; Charlotte Théroude; Irene T Schrijver; Thierry Roger
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

7.  MicroRNA miR-126 attenuates brain injury in septic rats via NF-κB signaling pathway.

Authors:  Anna Nong; Qingfeng Li; Zhijing Huang; Yunan Xu; Kebin He; Yuying Jia; Zhenyi Cen; Lianghua Liao; Yueyan Huang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.